Advertisement

Boston Scientific wins European approval to expand treatment with its Watchman stroke prevention device to patients with atrial fibrillation who can't take anticoagulants.

Boston Scientific's Watchman atrial appendage closure device

Boston Scientific (NYSE:BSX) won CE Mark approval in the European Union for expanded use of its Watchman heart device, the medical device giant announced over the weekend.

The new indication allows Boston Scientific to market the catheter-based clot-capture system to patients with atrial fibrillation who can't be treated with warfarin and new oral anticoagulants, according to a press release.

Advertisement
Advertisement